

Lifespot Health Ltd

lifespot-health.com



Vision and mission

Our Vision

To provide the most innovative inhaled therapies in the world.

Our Mission


To deliver the unique benefits of inhaled medication systems to patients in an affordable and high-quality format, supported by strong clinical evidence. We will achieve this by partnering with innovators and educators in their technical and therapeutic fields, to provide inhalation breakthrough therapies that deliver added value for patients, doctors, business partners, governments and stakeholders alike.

Our Values



Innovation

We accept that there is always a better way, the road to success is in finding it.




Transparency

We communicate clear goals, objectives and outcomes to all stakeholders.



Reliability

We do what we say we will do.



Integrity

Integrity leads our decision making.

The Lifespot Health team



Matthew Golden BSc. MMktg.
Chief Executive Officer

- Commercial healthcare Professional with almost 20 years' experience in the pharmaceutical industry
- Extensive Experience in both Australian and international markets.
- Strong experience launching mega brands such as Caduet and Eliquis and developing turnaround growth strategies for products such as Accupril and Pentrox (the 'Green Whistle').



Dr. Sud Agarwal
Medical Science Consultant

- Dr Agarwal is an anaesthetist and the Co-Founder of Cannvalate.
- Chief Medical Officer at Incannex Healthcare Ltd.
- Sud is considered a global cannabis key opinion leader advocating for clinically-validated cannabinoid treatment pathways.



Rodney Hannington
Non-Executive Chairman

- Over 15 years Consumer health and FMCG experience in Marketing and Strategic Services.
- International Experience across Asia and Middle East.
- Experienced ASX company director



Frank Cannavo
Non-Executive Director

- Experienced public company director with significant business and investment experience.
- Extensive experience in capital raisings, investment activities and IPO's.
- Entrepreneur with a strong network of investors and industry contacts in the public company sector throughout the Asia-Pacific region.

Justyn Stedwell
Non-Executive Director (Ad Interim)

- Justyn Stedwell is a professional Company Secretary, with almost 15 years' experience in ASX-listed companies.
- He is currently Company Secretary and Non-Executive Director of several ASX-listed companies.

Nova Taylor
Company Secretary

- Nova has extensive experience working in Company Secretary roles across numerous ASX-listed companies.
- Nova has completed a Bachelor of Laws at Deakin University.

Advancing our medical cannabis strategy

Focused on
medical
cannabis
systems since
2017

2017

- LSH lists on ASX – focused on the development and commercialisation of medical diagnostic and telemonitoring technologies.¹
- Explores growth opportunities in cannabis market.²
- Enters global medical cannabis market with Seng Vital JV agreement.³

2018

- Discussions with Nth American and Australasian cannabis producers.⁴
- Bodytel integrated with Seng Vital for CBD delivery systems.⁵
- Go-to-market cannabis strategy strengthened with 100% acquisition of Seng Vital.⁶
- Demonstrations with major cannabis players for integrated system licensing opportunities in Canada, USA, Australia and New Zealand.⁷

2019

- Hardware and repeat cannabis capsule sales identified as key revenue streams for LSH.⁸
- *Medihale* advanced medical vaporizer launches flower cartridge to better meet needs of cannabis inhalation market.⁹

2020

- 100% Australian based board and operations, and appointment of a new Australian based CEO.¹⁰
- Negotiates deal with ITSUWA to provide VOOM vapes to Australian market.
- \$72k sold to EC Pharma to supply cannabinoid e-liquids, RX via EC Pharma agreement with Cannvalate.
- Negotiates exclusivity agreement with ITSUWA for VOOM Vapes sales in Australia and NZ.


2021



- **Validating** the use of devices with clinical trials
- **Evidence for Registration** for use in acute medical conditions.
- **Partnering** for medical cannabis drug development
- Clinical trials program focused on **registration of combination device/drug** products with the TGA and FDA
- **EC Pharma Ongoing Repeat Sales of Medihale**

Key business focus

Short



Immediate Revenue

- Exclusive partnership with ITSUWA to sell 'Medihale' Voom vapes for use with Cannabis e-liquids.
- Supply deal with EC Pharma to provide Medihale vapes, with EC Pharma adding their proprietary Medical Cannabis E-liquid formulations for vaping for sale through SAS-B prescribing pathway via Cannvalate's doctor network.
- Cumulative repeat sales of \$189,489 Dec 20-Mar 21.


Medium



New Product Development

- Lifespot Health Ltd is partnering with developers to develop medical grade vape devices to meet the clinical needs of doctors and patients.
- Accurately dosed vape devices are essential for the medical cannabis industry and a key focus for Lifespot Health.

Long



Clinical Trials and Registration

- Lifespot Health Ltd's long term focus is to develop 1st to market, medically registered and integrated medical cannabis vape delivery systems.
- Partnering with EC Pharma (whose focus is medical cannabis drug development), Lifespot Health Ltd is planning a comprehensive clinical trials program focused on registration of combination device drug combination products with the TGA and FDA.

Building key strategic alliances



CANNVALATE

EC Pharma

- EC Pharma is licensed to wholesale, distribute and sell S3, S4 and S8 drug such as CBD and THC cannabinoids
- EC Pharma Pty Ltd also owns proprietary Cannabis E-liquid formulations for Vaping



ITSUWA

- Supplier of 'Medihale' vape devices

ELA CAPITAL

- Offering growth opportunities for LSH medical devices to enter the lucrative medical markets in North America and Europe.
- Strategic Investor in Lifespot Health Ltd

- Large prescribing network in Australia, including telehealth options allow access to Medical Cannabis for patients across Australia
- Australia's most trusted holistic plant-based health providers, having provided over 15,000 patient consultations
- Strategic Investor in Lifespot Health Ltd



- CRO focused on Medical Cannabis Clinical Research
- MCRC is also strategically partnered with Swinburne University in Melbourne to deliver high quality clinical trials




- Swinburne University in Melbourne is the strategic partner to MCRC delivering high quality clinical trials

The pathway to medical registration

Subject to TGA timelines and clinical trial participation we have multiple high value inflexions

2021 Q1 Q2 Q3 Q4 2022 Q1 Q2 Q3 Q4 2023 Q1 Q2 Q3 Q4 2024 Q1 Q2 Q3 Q4 2025 Q1 Q2 Q3 Q4

CBD Vape Acute Anxiety/Panic Attacks




* Value creation inflection points

THC Vape Acute Breakthrough Pain



CBD Vape Insomnia



SAS-B¹ Patient Sales Channel

S3² & S4³ Sales Channels →



1. SAS-B = Australia Therapeutic Goods Administration's Special Access Scheme program allow patient access to unregistered therapeutic goods in Australia; 2. S3 = Drugs & Drug/Device Combinations registered on the ARTG list as Schedule 3 for sale over the counter with pharmacy consultation (no doctors prescription required); 3. S4 = Drugs & Drug/Device Combinations registered on the ARTG list as Schedule 4 for sale at pharmacies only with a doctor's prescription.
NB Above timelines are indicative only and based on professional advice for planning only. Timelines are subject to change due to multiple factors influencing clinical trial timelines, including but not limited to regulatory & ethics approval requirements, variations in recruitment rates, budgetary considerations and government regulatory evaluation timeline changes.

Top Shareholders*

Rank	Shareholder Name	No. ORD Shares	Shareholder Ownership (%)
1	CANNVALATE PTY LTD	30,587,676	18.16
2	MID WEALTH PTY LTD	16,375,000	9.72
3	ELA CAPITAL INC	11,329,573	6.73
Total ORD Shares held by Top 3 LSH Shareholders:		58,383,832	34.66
Total ORD Shares held by balance of LSH Shareholders:		110,083,125	65.34

About the Top Shareholders

Cannvalate Pty Ltd was founded and funded in early 2018 by the Medical Community. The patient access division was established to demystify access to medicinal cannabis treatments. Today, Cannvalate is Australia's leading service provider and helps thousands of patients each and every month.

MID Wealth Pty Ltd is an investment vehicle owned by a network of service providers to healthcare professionals who make targeted investments in the Australian healthcare industry.

Ela Capital Inc has made multiple investments in the cannabis life sciences industry, beginning in 2015. Notably, Ela Capital was the founder and a significant shareholder of TerrAscend Corp (CNSX: TER), a multi-billion-dollar cannabis MSO in the United States. Ela Capital has over ten holdings in the cannabis and life sciences industries, with presence in all major medical cannabis markets globally.

LSH is Ela Capital's first investment in Australia and their participation will be both financial and advisory, offering growth opportunities for LSH medical devices to enter the lucrative medical markets in North America and Europe.



* As per Lifespot Health Ltd Shareholder Registry 25/03/2021

Summary*

Market Cap: \$19.4M
Stock Price: 11.5c
Shares on Issue: 168.5M



 Suite 103, 2 Queen Street, Melbourne

 (03) 8395 5446

 info@lifespot-health.com



1. GBP: AUD Exchange Rate 31/03/21 £1 = \$1.81 (<https://www.xe.com/currencyconverter/convert/?Amount=1&From=GBP&To=AUD>)
* Data Correct as of ASX & LSE close 31/03/2021

DISCLAIMER & IMPORTANT NOTICE

This presentation contains summary information about Lifespot Health Limited (“**Lifespot Health**” or “**LSH**” or “**Company**”) and its activities current as at the date of this presentation. It should be read in conjunction with Lifespot Health’s other periodic and continuous disclosure announcements filed with the Australian Securities Exchange, available at www.asx.com.au

This presentation is for information purposes only and is not a prospectus or product disclosure statement, financial product or investment advice or a recommendation to acquire Lifespot Health shares or other securities. It has been prepared without taking into account the objectives, financial situation or needs of individuals.

Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs and seek legal and taxation advice appropriate to their jurisdiction. Past performance is no guarantee of future performance.

No representation or warranty, expressed or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Lifespot Health and its related bodies corporate, or their respective directors, employees or agents, nor any other person accepts liability for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability from fault or negligence.

This presentation may contain forward-looking statements including statements regarding our intent, belief or current expectations with respect to Lifespot Health’s business and operations, market conditions, results of operations and financial condition, specific provisions and risk management practices. When used in this presentation, the words ‘plan’, ‘will’, ‘anticipate’, ‘expect’, ‘may’, ‘should’ and similar expressions, as they relate to Lifespot Health and its management, are intended to identify forward-looking statements.

Forward looking statements involve known and unknown risks, uncertainties and assumptions and other important factors that could cause the actual results, performances or achievements of Lifespot Health to be materially different from future results, performances or achievements expressed or implied by such statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date thereof.

Thank you

 Suite 103, 2 Queen Street, Melbourne

 (03) 8395 5446

 info@lifespot-health.com

Authorised by the Board of Directors

